000			021550000a22003370004500
003			EG-GICUC
005			20250223025610.0
008			061123s2004 ua a f m 000 0 eng d
040			_aEG-GICUC _beng _cEG-GICUC
041	0		_aEng
049			_aDeposite
097			_aM.Sc
099			_aCai01.12.02.M.Sc.2004.Mo.V.
100	0		_aMona Mohamed Abdelhakim
245	1	0	_aVascular endothelial growth factor and her - 2 / neu in breast cancer / _cMona Mohamed Abdelhakim ; Supervised Hamdy Mahmoud Hassaneen , Samar Kamal Kassim , Mohamed Ali Eldesoukey
246	1	5	_aدراسة عامل النمو الغشائى البطانى الوعائى والهير - 2 نيو فى حالات سرطان الثدي
260			_aCairo : _bMona Mohamed Abdelhakim , _c2004
300			_a167P : _bill ; _c30cm
502			_aThesis (M.Sc.) - Cairo University - Faculty Of Science - Department Of Biochemistry
520			_aBreast cancer represents an important problem in Women oncology A growing tumor induces the host endothelial cells to proliferate and supply the requisite vascular support allowing tumor development Vascular endothelial growth factor (VEGF) and HER2 - neu have been demonstrated to induce angiogenesis in epithelial tumors , this study included 45 tumors from patients with breast cancer in different grades and stages , in addition to 18 samples of benign breast lesions VEGF has been measured in the cytosolic fractions using enzyme immunoassay Tissue HER2 - neu was assessed using immunohistochemistry for its protein VEGF mean rank was significantly higher in breast cancer tumors compared to benign lesions (P=0001) Eleven samples were positive for Her2 - neu of them were in malignant group , with highest frequency in grade (IIIII) of the disease (11 / 45 , 25
530			_aIssued also as CD
653		4	_aHER2 - neu
653		4	_aVEGF
700	0		_aHamdy Mahmoud Hassaneen , _eSupervisor
700	0		_aMohamed Ali Eldesoukey , _eSupervisor
700	0		_aSamar Kamal Kassim , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aEnas _ecataloger
905			_aMustafa _eRevisor
942			_2ddc _cTH
999			_c16458 _d16458